Industry news

Cancer cell therapies could be approved next year: Juno, Kite Pharma

Deena Beasley / Reuters

A new wave of experimental cancer drugs that directly recruit the immune system's powerful T cells could begin reaching patients next year, according to companies presenting new data at the annual meeting of the American Society of Clinical Oncology.

ACS Report: Number of US Cancer Survivors Expected to Exceed 20 Million by 2026

ACS News Center

A new report by the American Cancer Society – in collaboration with the National Cancer Institute – estimates there are more than 15.5 million cancer survivors alive in the US today, and that number will grow to more than 20 million by 2026. This includes everyone who’s ever had cancer, from the time of diagnosis for the rest of their life. The report, “Cancer Treatment & Survivorship Facts & Figures 2016-2017,” and an accompanying journal article in CA: A Cancer Journal for Clinicians were released June 2, 2016.

04 June 2016

Presence of AR-V7 in Circulating Tumor Cells Validated as Predictive Biomarker for Advanced Prostate Cancer Treatment by Memorial Sloan Kettering and Epic Sciences

Detecting AR-V7 positive tumor cells circulating in the blood of an advanced prostate cancer patient predicts that he will not only fail the commonly-prescribed androgen receptor signaling inhibitors (ARSI), abiraterone and enzalutamide, but that he will survive significantly longer if treated with a taxane based chemotherapy regimen.

Big Pharma leads the charge in TV ad spending increases, analyst report finds

Beth Snyder Bulik / FiercePharmaMarketing

And the spend goes on. The latest pharma ad news is from Morgan Stanley, which notes pharma companies are leading the way in a national TV spending upswing. 

Competition watchdog details vaccine market concerns

Eric Sagonowsky / Fierce Pharma

Where some see a small cadre of top-notch vaccine companies, others might see an oligopoly. Where some see innovation, others see hard-to-copy jabs that keep generics away and prices high.

How can patients get their money's worth from cancer meds?

Tracy Staton / Fierce Pharma

The American Society of Clinical Oncology stepped up the drug-cost debate last year when it proposed a tool to help doctors and patients compare potential treatments. Now, after collecting critiques from providers, patients and the pharma industry, the influential organization has rolled out a new version of that “value framework.” 

India plans drug industry foreign investment scorecard

EJ Lane / FeircePharmaAsia

India's Commerce and Industry Ministry plans to measure the impact of foreign investment on the drug industry in a step that will be closely watched for any conclusions for--or against--more activity in the sector.

White House posts data security framework for Precision Medicine

Nick Paul Taylor / Fierce Biotech

The White House has released a data security framework to help organizations participating in the Precision Medicine Initiative (PMI) protect information on individuals. Officials have opted against taking a prescriptive approach and have instead tried to create a framework that organizations can adapt to their specific needs and responsibilities.

China to probe drug, device pricing among domestic, foreign firms

EJ Lane / FeircePharmaAsia

China's National Development and Reform Commission (NDRC) will launch an investigation into all aspects of drug and medical device sales and prices among domestic and foreign firms in a step that could lead to enforcement action.

01 June 2016

Clearside Biomedical, Inc. Announces Pricing of Initial Public Offering

Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced the pricing of its initial public offering of 7,200,000 shares of its common stock at a public offering price of  $7.00  per share.